Variants

FDA Updates Recommendation Around AstraZeneca’s Evusheld

The FDA has revised its emergency use authorization for AstraZeneca’s Evusheld, a monoclonal antibody treatment for COVID-19. Due to emerging data, it has been observed that the original 150mg dose of each monoclonal antibody may be less likely to prevent infection than originally indicated. Thus, the FDA has authorized a double dose of each antibody for immunocompromised patients.

Read More »

FDA Expands Authorization Around Remdesivir to Treat COVID-19

On January 21, the FDA expanded the use of remdesivir to non-hospitalized adults and children who have mild-to-moderate COVID-19, who are at risk of severe disease. Previously, remdesivir was only available to hospitalized patients. This decision was based on a clinical trial including 562 participants with mild-to-moderate COVID-19, who had displayed symptoms within the previous 7 days and had at least one risk factor for severe disease.

Read More »

Results of Com-Cov Mix-and-Match Vaccine Study

The Com-Cov2 study tested the efficacy and safety of mix-and-matching COVID-19 vaccines, including Pfizer, AstraZeneca, Moderna and Novavax. Moderna or Novavax vaccines were administered 8-12 weeks after a first dose of the Pfizer or AstraZeneca vaccine, measuring for IgG antibodies at 28 days after the second dose.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.